Checkpoint modulation in melanoma: An update on ipilimumab and future directions Review uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Immunotherapy
  • Melanoma

abstract

  • Ipilimumab, an anti-cytotoxic T-lymphocyte antigen 4 antibody, was the first therapy demonstrated to improve overall survival in melanoma. Since ipilimumab's approval by the FDA in 2011, a wealth of data has amassed, helping clinicians to optimize its use. We have learned how to mitigate the adverse effects of ipilimumab, identified its effects in melanoma subpopulations such as those with brain metastases, uveal melanoma, and mucosal melanoma, discovered potential biomarkers of activity, and investigated its use in combination with other therapeutic modalities. These discoveries have paved the way for rapid development of second-generation immunomodulatory antibodies such as inhibitors of the programmed cell death 1 receptor axis. These new agents hold promise as monotherapy, but perhaps the greatest allure lies in the possibility of combining these agents in synergistic multidrug regimens.

publication date

  • October 2013

Research

keywords

  • Review

Identity

Language

  • eng

PubMed Central ID

  • PMC3799873

Digital Object Identifier (DOI)

  • 10.1007/s11912-013-0337-1

PubMed ID

  • 23933888

Additional Document Info

start page

  • 500

end page

  • 8

volume

  • 15

number

  • 5